A UCLA study shows that a new treatment combining a radioactive drug with radiation therapy could help delay hormone therapy ...
For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...
A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT) ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
A shorter radiation course improved quality of life among men with intermediate-risk, localized prostate cancer, according to ...
Only men with prostate tumors of the luminal B subtype benefited from adding apalutamide to salvage radiation in the phase 2 ...
A phase 2 trial tested the efficacy of local stereotactic body radiation therapy (SBRT) use after radical prostatectomy.
A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate ...
Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic ...
MedPage Today on MSN
Hormone Therapy Added to Radiotherapy Benefits Some With Recurrent Prostate Cancer
SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits ...
News Medical on MSN
ASTRO: Targeted radioactive therapy for recurrent prostate cancer, new SBRT approaches, 5DCT-guided imaging advances and more
Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...
(UroToday.com The 2025 ASTRO annual meeting featured a prostate cancer session and a presentation by Dr. Beth Neilsen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback